Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
Holders of 5% or more of ARQT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arcutis Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. | 13D/A | 7.50%8.94M shares | – | Feb 9, 20212 filings | Aug 20, 2025 | SEC |
| Rubric Capital Management LP | 13G/A | 6.75%8.27M shares | – | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Polar Capital Holdings Plc | 13G | 5.28%6.61M shares | +1.08 ppfrom 4.20% | May 15, 20253 filings | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Arcutis Biotherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20266:20 AM ET | Polar Capital Holdings Plcand 1 other | 13G | 5.28%6.61M shares | +1.08 ppfrom 4.20% | Jun 30, 2026 | SEC |
| Aug 7, 20268:42 AM ET | State Street Corp | 13G | 4.70%5.82M shares | −0.40 ppfrom 5.10%Below 5% | Jun 30, 2026 | SEC |
| May 12, 20269:55 AM ET | State Street Corp | 13G | 5.10%6.30M shares | New | Mar 31, 2026 | SEC |
| May 8, 202611:08 AM ET | Prudential Financial Inc | 13G/A | 4.30%5.30M shares | −1.40 ppfrom 5.70%Below 5% | Mar 31, 2026 | SEC |
| May 6, 20264:11 PM ET | Jennison Associates LLC | 13G/A | 4.00%4.98M shares | −1.50 ppfrom 5.50%Below 5% | Mar 31, 2026 | SEC |
| Mar 26, 202611:13 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 13, 20264:08 PM ET | Rubric Capital Management LPand 1 other | 13G/A | 6.75%8.27M shares | – | Dec 31, 2025 | SEC |
| Feb 13, 20263:08 PM ET | Prudential Financial Inc | 13G/A | 5.70%7.08M shares | −4.40 ppfrom 10.10% | Dec 31, 2025 | SEC |
| Jan 30, 20264:21 PM ET | Jennison Associates LLC | 13G/A | 5.50%6.76M shares | −4.70 ppfrom 10.20% | Dec 31, 2025 | SEC |
| Oct 6, 20255:46 PM ET | Jennison Associates LLC | 13G/A | 10.20%12.3M shares | +0.60 ppfrom 9.60% | Sep 30, 2025 | SEC |
| Aug 20, 20255:19 PM ET | Frazier Life Sciences VIII, L.P.and 19 others | 13D/A | 7.50%8.94M shares | – | Aug 18, 2025 | SEC |
| Aug 14, 20258:04 AM ET | Polar Capital Holdings Plcand 2 others | 13G/A | 4.20%5.01M shares | −1.45 ppfrom 5.65%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20255:41 PM ET | Prudential Financial Inc | 13G/A | 10.10%12.0M shares | – | Mar 31, 2025 | SEC |
| May 15, 202510:13 AM ET | Polar Capital Holdings Plcand 2 others | 13G/A | 5.65%6.71M shares | – | Mar 31, 2025 | SEC |
| May 8, 20255:59 PM ET | Jennison Associates LLC | 13G/A | 9.60%11.4M shares | – | Mar 31, 2025 | SEC |
| Feb 9, 2021 | Frazier Life Sciences VIII, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 9, 2021 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 8, 2021 | Bain Capital Life Sciences Fund, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Arcutis Biotherapeutics, Inc. shares.
No Form 144 notices for Arcutis Biotherapeutics, Inc. are on file.